TJC-0316

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameTJC-0316
Drug Alias NameTJC-0316
ClassificationSmall molecules
Mechanisms of ActionEctonucleotide pyrophosphatase/phosphodiesterase 2 inhibitors
TargetsEctonucleotide pyrophosphatase/phosphodiesterase 2
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTaiwanj Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiwanj Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A